- Facing pharmacy trends for the remainder of the year
- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
- Senate passes Drug Quality and Security Act
- Roxane Labs' generic prostate drug gets tentative approval from FDA
- Generic drug prices spike, but PBMs' reimbursement rates don't keep up, NCPA study finds
CINCINNATI, Ohio — Drug maker Prasco Labs has launched an authorized generic version of a drug used to treat heavy menstrual bleeding, the company said Monday.
Prasco announced the launch of tranexamic acid tablets in the 650 mg strength, an authorized generic version of Ferring Pharmaceuticals' Lysteda. Authorized generics are branded drugs marketed under their generic names at a discount, usually through third-party companies, to compete with Food and Drug Administration-approved generics.
"We are pleased to welcome Ferring Pharmaceuticals into Prasco's family of brand partners with the introduction of the authorized generic of Lysteda tablets," Prasco CEO Chris Arington said. "With the choice of tranexamic acid tablets, customers benefit from the same consistent supply and quality of the brand they are accustomed to."